Recombinant Activated Factor VII in Cardiac Surgery: A Meta-analysis

Impact of aspirin use on morbidity and mortality in massively transfused cardiac surgery patients: a propensity score matched cohort study

“…Results have been inconsistent with these agents though, depending on the population studied. There are also persistent safety concerns including renal failure with aprotinin and arterial and venous thromboses with rFVIIa [28][29][30]. Some studies have suggested that perioperative aspirin use may be associated with increased risks of transfusion and bleeding, but in massively transfused patients the contribution to bleeding is probably minimal.…”

Épidémiologie des accidents vasculaires cérébraux périopératoires

“…Ainsi, l'utilisation du facteur VII activé est limité e aux situations hé morragiques incontrô lables en raison du risque é levé d'AVCI [78,79]. À l'inverse, l'acadé sine ré duit aussi bien l'incidence d'infarctus du myocarde que celui de l'AVCI aprè s pontage coronarien [80].…”

Successful Use of Factor VIIa to Control Life-threatening Post-operative Haemorrhage in a Patient on Extra-Corporeal Membrane Oxygenation

“…Although it is yet to be granted official licencing to use in post-cardiac surgery, more evidence is mounting in its support [3][4][5][6][7][8][9]. A recent meta-analysis [1] and placebocontrolled RCT [2] both confirmed its efficacy in reducing bleeding whilst maintaining an acceptable side effect profile. Furthermore, its use has been increasing rapidly with 300 doses prescribed in 1999 to 4500 doses in 2004 [10].…”